相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A
Arelis Salas et al.
BLOOD (2011)
A potent sphingomyelinase inhibitor from Cordyceps mycelia contributes its cytoprotective effect against oxidative stress in macrophages
Shwu-Huey Wang et al.
JOURNAL OF LIPID RESEARCH (2011)
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells
A. Puissant et al.
LEUKEMIA (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Glycogen synthase kinase 3: more than a namesake
Geetha Vani Rayasam et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
Jia Luo
CANCER LETTERS (2009)
Glycogen Synthase Kinase-3β Facilitates IFN-γ-Induced STAT1 Activation by Regulating Src Homology-2 Domain-Containing Phosphatase 2
Cheng-Chieh Tsai et al.
JOURNAL OF IMMUNOLOGY (2009)
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
Susanne Schiffmann et al.
JOURNAL OF LIPID RESEARCH (2009)
Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers
Rebecca L. Shaner et al.
JOURNAL OF LIPID RESEARCH (2009)
Glycogen Synthase Kinase-3β Mediates Endoplasmic Reticulum Stress-Induced Lysosomal Apoptosis in Leukemia
Wei-Ching Huang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL
A. A. Mian et al.
LEUKEMIA (2009)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway
Chia-Ling Chen et al.
BLOOD (2008)
Principles of bioactive lipid signalling: lessons from sphingolipids
Yusuf A. Hannun et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells
Q-F Li et al.
ONCOGENE (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
GSK-3β acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis
Chiou-Feng Lin et al.
JOURNAL OF CELL SCIENCE (2007)
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer
Qingqing Ding et al.
CANCER RESEARCH (2007)
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells
Yusuf Baran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Addolorata Maria Luce Coluccia et al.
EMBO JOURNAL (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Glycogen synthase kinase-3 - An overview of an over-achieving protein kinase
Lisa Kockeritz et al.
CURRENT DRUG TARGETS (2006)
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
E. Tamborini et al.
ONCOGENE (2006)
Janus kinase 2: A critical target in chronic myelogenous leukemia
Ajoy K. Samanta et al.
CANCER RESEARCH (2006)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network
H Rosen et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs
V Gouazé et al.
CANCER RESEARCH (2005)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
KJ Aichberger et al.
BLOOD (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
N von Bubnoff et al.
LEUKEMIA (2005)
The glamour and gloom of glycogen synthase kinase-3
RS Jope et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
E Tamborini et al.
GASTROENTEROLOGY (2004)
Differential Effects of Glycolipid Biosynthesis Inhibitors on Ceramide-Induced Cell Death in Neuroblastoma Cells
Erhard Bieberich et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3β pathways
K Sawafuji et al.
LEUKEMIA & LYMPHOMA (2003)
Autoinhibition of Bcr-Abl through its SH3 domain
KM Smith et al.
MOLECULAR CELL (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
HM Kantarjian et al.
BLOOD (2003)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
OG Ottmann et al.
BLOOD (2002)
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
SH Xie et al.
ONCOGENE (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
